Selected Posters and Abstracts
HIV-HCV Coinfection
[P312] Safety assessment of lopinavir/ritonavir (LPV/r) in HIV+ and hepatitis C (HCV) co-infected patients
[P322] Neuro-psychological disturbances in HIV/HCV co-infected and HCV mono-infected patients eligible to receive PegIFNα
[P314] Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV co-infected patients
[P319] Prevalence, etiology and stage of liver cirrhosis in HIV-infected patients
[P320] Prevalence and therapeutic significance of anti-interferon antibodies in HCV/HIV co-infected patients
[P324] Sustained clearance of HCV after immunologic restoration syndrome in an HIV-HCV co-infected patient
[P323] HIV-HCV co-infection – time to act?

[P313] Factors associated with progression of liver fibrosis in HIV/HCV co-infected patients: influence of antiretrovirals and metabolic disturbances


Ribavirin Plays a Critical Role in Early Virological Response in HIV-HCV Coinfected Patients

Pegasys Plus Weight-Based Ribavirin Produces High Response Rates in HIV-HCV Coinfected Patients

<— Conference Main Page

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva

Norvir
Prezista

Reyataz
Viracept


Nucleoside / Nucleotide Reverse Transcriptase Inhibitors

Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen


non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor

Sustiva
Viramune

Entry Inhibitors
Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada